Aerosolized amphotericin B as prophylaxis for invasive pulmonary aspergillosis: a meta-analysis  by Xia, Di et al.
International Journal of Infectious Diseases 30 (2015) 78–84Aerosolized amphotericin B as prophylaxis for invasive pulmonary
aspergillosis: a meta-analysis
Di Xia a,1, Wen-Kui Sun a,1, Ming-Ming Tan a, Ming Zhang a, Yuan Ding a, Zhi-Cheng Liu b,
Xin Su a,*, Yi Shi a,*
aDepartment of Respiratory and Critical Care Medicine, Jinling Hospital, Medical School of Nanjing University, Nanjing, People’s Republic of China
b Southern Medical University, Guangdong, People’s Republic of China
A R T I C L E I N F O
Article history:
Received 6 October 2014
Received in revised form 3 November 2014
Accepted 4 November 2014
Corresponding Editor: Eskild Petersen,
Aarhus, Denmark
Keywords:
Aerosolized amphotericin B
Invasive pulmonary aspergillosis
Prophylaxis
Meta-analysis
Immunosuppression
S U M M A R Y
Objectives: Invasive pulmonary aspergillosis (IPA) is associated with high mortality in high-risk
(immunosuppressed) patients. Many studies have investigated whether prophylactic inhalation of
amphotericin B (AMB) reduces the incidence of IPA, but no deﬁnitive conclusions have been reached. The
present meta-analysis was performed to evaluate the efﬁcacy of prophylactic inhalation of AMB for the
prevention of IPA.
Methods: MEDLINE and other databases were searched for relevant articles published until December
2013. Randomized controlled trials that compared aerosolized AMB with placebo were included. Two
reviewers independently assessed and extracted the data of all trials.
Results: Six animal studies and two clinical trials involving 768 high-risk patients were eligible. The
animal studies showed lower overall mortality rate among animals that underwent aerosolized AMB
prophylaxis (odds ratio (OR) 0.13, 95% conﬁdence interval (CI) 0.08–0.21). Similarly, the clinical trials
showed a lower incidence of IPA among patients who underwent aerosolized AMB prophylaxis (OR 0.42,
95% CI 0.22–0.79).
Conclusions: This analysis provides evidence supporting the notion that the prophylactic use of
aerosolized AMB effectively reduces the incidence of IPA among high-risk patients.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Invasive aspergillosis (IA) is an increasingly frequent cause of
morbidity and mortality in immunosuppressed patients, especially
those undergoing solid organ or hematopoietic stem cell transplan-
tation and those with prolonged neutropenia.1 Invasive pulmonary
aspergillosis (IPA) is the most common form of IA. Despite the fact
that new non-invasive laboratory methods have been developed to
improve the diagnostic yield, including the Aspergillus galacto-
mannan assay, the (1,3)-b-D-glucan assay, and PCR techniques, IPA
remains associated with a high fatality rate. In one systematic
review, 70% of 1941 patients with aspergillosis exhibited pulmonary
involvement, and the case-fatality rate was >60% despite the
administration of intensive antifungal therapy.2 Therefore, prophy-
lactic therapy is important in high-risk patients. However, there is no
consensus on the optimal agent or administration route.* Corresponding authors. Tel.: +86 25 80860148; fax: +86 25 80860148.
E-mail addresses: suxinjs@163.com (X. Su), shiyi56@126.com (Y. Shi).
1 Both authors contributed equally to this article and were co-ﬁrst authors.
http://dx.doi.org/10.1016/j.ijid.2014.11.004
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Amphotericin B (AMB) was the ﬁrst commercially signiﬁcant
antifungal drug. It has a broad spectrum of activity against many
different fungal species and has been the standard IA treatment for
decades.3 Although new agents such as voriconazole and itracona-
zole have been recommended for patients with IPA, AMB is still
considered to be the primary therapeutic agent for some patients
and is included in many prophylactic regimens for fungal infection.4
One study showed that the prophylactic administration of intrave-
nous AMB to patients undergoing bone marrow transplantation was
associated with fewer fungal microorganisms and higher survival
ratescompared to the placebo group; however, signiﬁcantly greater
numbers of infusion-related side effects occurred.5 Therefore,
aerosolized AMB represents an attractive alternative for the
prevention of IPA because the administration of drugs by inhalation
ensures a high drug concentration in the respiratory tract and a
lower incidence of side effects.
Since the 1990s, many studies have been conducted to elucidate
the feasibility, tolerability, and effectiveness of aerosolized AMB
for the prevention of Aspergillus infection.6–11 A retrospective
study of 99 patients who underwent heart transplantation withciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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inhalation of AMB demonstrated a signiﬁcant difference between
the two groups; prophylaxis with AMB effectively prevented
IPA.12 Another retrospective study evaluated the impact of
prophylactic AMB inhalation on IA in 611 recipients of allogeneic
stem cell transplantation and examined the recipients’ tolerance
of the inhalation therapy. The incidence of IA was lower in the
prophylactic AMB inhalation group than in the placebo group,
and the inhalation therapy was well tolerated.13 However, other
studies have reached different conclusions. In another study that
investigated the effectiveness of aerosolized AMB as prophylaxis
against IPA, 28% of the patients developed proven or possible
infections. Inhalation of AMB does not appear to be useful in
preventing IPA in patients with granulocytopenia.14
The present meta-analysis was performed to assess the
prophylactic effect of aerosolized AMB against IPA by examining
the IPA-associated mortality among immunocompromised ani-
mals and the incidence of IPA among high-risk patients.
2. Materials and methods
2.1. Search strategy
Two separate electronic searches were conducted to identify
eligible studies. MEDLINE, Embase, the Chinese Biomedical
Literature Database, and the Cochrane Library were searched for
relevant articles published until December 25, 2013. The following
search terms were used: ‘‘inhaled’’ or ‘‘inhalational’’ or ‘‘aerosol’’ or
‘‘aerosolized’’ or ‘‘nebulized’’ or ‘‘nebulization’’ and ‘‘amphoteri-
cin’’. No limitations were placed on language or year. The reference
lists of related reviews and original papers were also checked for
relevant trials.
2.2. Study selection
The following inclusion criteria were established before article
collection. Animal studies were required to (1) be randomized
controlled trials, (2) compare aerosolized AMB with placebo,
(3) administer aerosolized AMB before exposure to Aspergillus
fumigatus conidia, and (4) provide the number of animals
sacriﬁced. Human studies were required to (1) be randomized
controlled trials, (2) include adult patients (aged >18 years)
scheduled to receive chemotherapy with an anticipated duration
of neutropenia <0.5  109 cells/l of 10 days, (3) compare
aerosolized AMB with placebo, and (4) administer aerosolized
AMB before any signs of proven or probable IPA. When an
individual author published several articles involving the same
patient population, only the most complete article was included.
Studies that did not meet the above-described inclusion criteria
were excluded from the meta-analysis.
2.3. Quality assessment
Clinical randomized controlled trials were assessed using the
Jadad scale.15 This scale is used to assess trials according to
the following three questions: (1) Was the study described as
randomized (i.e., did it use the terms ‘randomly’, ‘random’, or
‘randomization’)? (0–2 points); (2) Was the study described as
double-blind? (0–2 points); (3) Was there a description of
withdrawals and dropouts? (0–1 point). A study can receive a
maximum Jadad score of 5 points.
2.4. Data extraction
Two reviewers (DX and WKS) independently carried out the
data extraction and validity assessment, and any discrepancieswere resolved by discussion. For the animal studies, a piloted data
extraction form was used to collect information on the ﬁrst
author, year of publication, animal species, number of animals in
each group, method of inducing immunosuppression, details of
experimental drug and placebo treatments, follow-up duration,
and ﬁnal mortality rate. For the clinical trials, a data extraction
form was used to collect information on the ﬁrst author, year of
publication, country of origin, Jadad score, number of patients in
each group, and incidence of IPA.
2.5. Statistical analysis
The results of prophylaxis for dichotomous outcomes are
expressed as odds ratios (ORs) with 95% conﬁdence intervals
(CIs) for both the animal studies and clinical trials. The I2 statistic
was used to determine the extent of inconsistency and thus
assess the heterogeneity between trials. We considered an I2-value
of >50% and a p-value of <0.1 to indicate heterogeneity. A ﬁxed-
effects model was used to estimate the effects of aerosolized
AMB. However, if signiﬁcant heterogeneity was present, a random-
effects model was used to generate a more conservative estimate.
Publication bias among the randomized controlled trials
involving animals was examined by visual inspection of a funnel
plot. Publication bias was suspected when the funnel plot was
asymmetrical; in such cases, Egger’s test was performed for further
analysis of bias.
Sensitivity analyses were conducted by comparing the esti-
mates derived from the random- and ﬁxed-effects models. One
study that used AMB inhalation powder (ABIP) as the prophylactic
drug was excluded from the sensitivity analyses because this drug
is not widely used.
Subgroup analyses of the animal studies were performed to
explore important differences that might be expected to alter the
magnitude of the prophylactic effect.
3. Results
3.1. Study selection and characteristics
Figure 1 shows the study selection process. In total, 1362 poten-
tially relevant citations were identiﬁed from the electronic search,
1348 of which were determined to be non-relevant after reading the
titles and abstracts. The remaining 14 studies underwent full review
by the two above-mentioned independent reviewers. Eight of these
14 studies met the inclusion criteria and were subjected to the meta-
analysis.16–23Six studies were initially thought to fulﬁll the inclusion
criteria, but were excluded after detailed examination. One study
was not a randomized controlled trial,24 one evaluated the
therapeutic rather than the prophylactic efﬁcacy of aerosolized
AMB,25one evaluated the beneﬁcial effect of intravenous rather than
aerosolized AMB,26 one evaluated the beneﬁcial effect of aerosolized
AMB on the fungal burden rather than on mortality,27 and two were
duplicate publications.10,28 Of the eight remaining eligible studies,
six were animal randomized controlled trials16–21 and two were
human randomized controlled trials.22,23
In all six animal studies, a systemic steroid and/or cyclophos-
phamide was used to induce immunosuppression. The fungal
inoculation and drug administration methods were described in
detail. The various formulations of aerosolized AMB were AMB
desoxycholate (AMB-d), liposomal AMB (L-AMB), AMB lipid
complex (ABLC), AMB colloidal dispersion (ABCD), and ABIP.
Table 1 lists the details of the six animal studies included in this
meta-analysis.
In both of the human studies, randomization was performed
using a computer-generated blocked list. Both studies included a
description of the patients who withdrew from or dropped out of
Figure 1. Flow diagram of study selection method
AMB: amphotericin B
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in one trial and AMB-d in the other. The details of these two trials
are given in Table 2. Both clinical trials mentioned the potential
toxic effects of the therapy, and one described the toxic effects in
detail.22 For the patients who received aerosolized L-AMB, the
median serum creatinine levels after the last inhalation were not
greater than the baseline levels, but coughing was observed more
frequently than at baseline.23 About two-thirds of patients who
received aerosolized AMB-d reported at least one unpleasant
sensation such as coughing, a bad taste, nausea, or others.22 No
serious drug-related adverse events were reported.Table 1
Characteristics of the animal studies included in the meta-analysis
Author
(year)
Animal Method of inducing immunosuppression 
Schmitt (1988) Rat Steroid (100 mg/kg) administered 2 weeks bef
fungal inoculation and continued throughout t
experiment
Niki
(1991)
Rat Steroid (150 mg/kg) administered three times 
2 weeks before and 1 week after fungal inocul
Allen
(1994)
Mouse Steroid (150 mg/kg) administered 1 day before
1 day after fungal inoculation
Cicogna (1997) Rat Steroid (150 mg/kg) administered for 2 weeks u
day of fungal inoculation or steroid (150 mg/k
administered for 2 weeks before fungal inoculat
continued throughout the experiment
Ruijgrok (2005) Rat Cyclophosphamide (90 mg/kg) administered 5 
before and cyclophosphamide (60 mg/kg) admin
every 4 days after fungal inoculation
Kirkpatrick (2012) Guinea pig Cyclophosphamide (250 mg/kg) and steroid (2
kg) administered 2 days before and 3 days after
inoculation
AMB, amphotericin B; AMB-d, amphotericin B desoxycholate; L-AMB, liposomal amph
powder.3.2. Meta-analysis results
Six studies of immunosuppressed animals were eligible for
inclusion in the meta-analysis. The overall mortality of animals
treated with prophylactic inhalation of AMB was lower than that of
animals treated with placebo. No heterogeneity was observed
(I2 = 7%, p = 0.36) and a ﬁxed-effects model was used. The combined
OR for all six eligible studies was 0.13 (95% CI 0.08–0.21;
p < 0.00001) (Figure 2), indicating that the prophylactic use of
aerosolized AMB was effective in immunocompromised animals.
No signiﬁcant difference (p = 0.28) was observed between theAspergillus
inoculum dose
AMB administration
dose and time prior to
pulmonary inoculation
Time point of
mortality measure
ore
he
106 conidia AMB-d: 1.6 mg/kg
2 days
21 days after
fungal inoculation
weekly,
ation
106 conidia AMB-d: 1.6 mg/kg
48 h
4 weeks after
fungal inoculation
 until 1.4  106
1.5  107
1.3  108 conidia
L-AMB: 6.05 mg/kg
AMB-d: 6.73 mg/kg
1, 2, and 3 days
9 days after fungal
inoculation
ntil the
g)
ion and
106 conidia ABLC: 0.4, 0.8, and
1.6 mg/kg
AMB-d: 1.6 mg/kg
ABLC: 1.6 mg/kg
2 days
14 days after
fungal inoculation
days
istered
1.5  105 conidia AMB-d: 2 mg/ml
L-AMB: 4 mg/ml
ABLC: 4 mg/ml
1, 2, and 6 weeks
12 days after
fungal inoculation
50 mg/
 fungal
1  108 conidia ABIP: 0.05, 0.50, 4.00,
and 10.00 mg/kg
24 h
11 days after
fungal inoculation
otericin B; ABLC, amphotericin B lipid complex; ABIP, amphotericin B inhalation
Table 2
Characteristics of clinical trials included in the meta-analysis
Author
(year)
Study period Study region Patients Jadad
quality
score
Treatment
group,
IPA/total
Placebo
group,
IPA/total
Schwartz (1999) 1993/03–1996/04 Germany Adult patients with hematological disease and neutropenia 3 10/227 11/155
Rijnders (2008) 2000/11–2006/01 Netherlands Adult patients with hematological disease or solid tumors
and neutropenia
5 6/139 18/132
IPA, invasive pulmonary aspergillosis.
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(Figure 3A) and that of lipid-associated AMB formulations (OR 0.06,
95% CI 0.03–0.14; p < 0.00001) (Figure 3B).
Two human trials involving 768 high-risk patients were eligible
for inclusion in the meta-analysis. The incidence of IPA in patients
who underwent administration of aerosolized AMB during
neutropenic episodes was lower than that of patients who
underwent administration of placebo (4.4% vs. 10.4%, respectively).
No evidence of heterogeneity was observed (I2 = 21%, p = 0.26), and
a ﬁxed-effects model was used. Aerosolized AMB demonstrated a
signiﬁcant preventive advantage over placebo in terms of a lower
incidence of IPA (OR 0.42, 95% CI 0.22–0.79; p = 0.007) (Figure 4).
3.3. Sensitivity analyses
Despite the absence of statistical heterogeneity, signiﬁcant trial
heterogeneity was present across the analyzed studies (different
animal types, AMB formulations, AMB doses, etc.). Therefore, weFigure 2. Forest plot showing effect of prophylactic aerosolized amphotericin B on mo
M-H: Mantel–Haenszel analysis, CI: conﬁdence intervalperformed a sensitivity analysis of the six animal studies by
repeating the main computations using a random-effects model.
The random-effects model did not signiﬁcantly change the results
of our meta-analysis. Similarly, other sensitivity analyses showed
no changes in the results after exclusion of speciﬁc studies
(Table 3). Therefore, the results of this meta-analysis are stable.
3.4. Publication bias
The funnel plot of the animal studies was asymmetrical,
suggesting possible publication bias (Figure 5). Egger’s test was
then performed to check for bias; the result was signiﬁcant (p =
0.01), again suggesting possible publication bias.
4. Discussion
This meta-analysis has shown that aerosolized AMB can help to
prevent IA in both immunocompromised animals and high-riskrtality of immunosuppressed animals
Figure 3. Forest plot showing effect of prophylactic aerosolized amphotericin B desoxycholate (A) and lipid-associated amphotericin B (B) on mortality of immunosuppressed
animals.
M-H: Mantel–Haenszel analysis, CI: conﬁdence interval
Figure 4. Forest plot showing effect of prophylactic aerosolized amphotericin B on incidence of invasive pulmonary aspergillosis in high-risk patients
M-H: Mantel–Haenszel analysis, CI: conﬁdence interval
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etic stem cell or solid organ transplantation, patients with
malignancies undergoing intensive chemotherapy, and patients
with other causes of immunosuppression. Asymptomatic patients
with Aspergillus galactomannan in the bronchoalveolar lavageﬂuid or serum may especially beneﬁt from the prophylactic use of
aerosolized AMB.
Aerosolized AMB is relatively safe. To the best of our knowledge,
no serious drug-related adverse events have been reported in
association with its prophylactic use. In one study, patients who
Table 3
Sensitivity analyses for the primary outcome
Number
of studies
OR (95% CI) p-Value
Random-effects model 6 0.13 (0.07–0.22) <0.00001
Exclusion of one study
that used ABIP
5 0.06 (0.03–0.12) <0.00001
OR, Odds ratio; 95% CI, 95% conﬁdence interval; ABIP, amphotericin B inhalation
powder.
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prophylaxis considered the inhalations to be unpleasant mostly
because of a bad taste or the development of coughing. However,
the inhalation therapy was feasible and safe, and no severe side
effects occurred.29 Monforte et al. found that nebulized L-AMB for
prophylactic treatment of Aspergillus infection exhibits neither
signiﬁcant systemic absorption nor adverse effects on respiratory
function.30 They also found that nebulized L-AMB does not change
the lipid content of pulmonary surfactant. This agent safely and
effectively prevents Aspergillus spp infection in lung transplant
recipients.31
Different AMB formulations may have different clinical effects
because each has a distinct pharmacological proﬁle. Drew et al.
concluded that patients who received AMB-d are more likely to
experience adverse events.32 However, our subgroup analysis of
animal studies showed no signiﬁcant difference between AMB-d
and lipid-associated AMB formulations. This result is consistent
with that obtained in a previous observational study in which
104 consecutive patients who underwent prophylaxis with
aerosolized L-AMB were compared with 49 historical control
subjects who received aerosolized AMB-d. The two groups
exhibited similar rates of Aspergillus infection and side effects
such as transitory breathing difﬁculty, nausea, and broncho-
spasm.33 One systematic review and meta-analysis showed no
difference between the adverse events associated with inhaled
AMB-d and those associated with lipid formulations of inhaled
AMB.34 A worldwide survey on antifungal prophylaxis in patients
undergoing lung transplantation also revealed that inhaled lipid
formulations of AMB are effective and being used with increased
frequency.35 Therefore, lipid formulations may be more effective
than AMB-d in preventing IPA.
New formulations of aerosolized AMB have recently been
developed. Lipid nanoemulsions may serve as successful nano-
carriers for the delivery of AMB to the peripheral airways.36
Nonionic surfactant vesicles that deliver AMB to the lungsFigure 5. Funnel plot showing absence of small negative studies suggestive of small
publication bias.reportedly enhance pulmonary delivery while minimizing sys-
temic exposure and toxicity.37 Further studies comparing the
effects of these various formulations on the prevention of IA are
also needed.
New antifungal agents in the azole group have been developed
in recent years . They are also prescribed as prophylaxis against
IPA. Neoh et al.38 conducted a retrospective cohort study to
explore the effect of prophylactic voriconazole in lung transplant
recipients. They concluded that preemptive voriconazole treat-
ment resulted in a lower incidence of IA and a lower IA-related
mortality rate. Another retrospective study suggested that the
routine use of prophylactic voriconazole against Aspergillus
infection in lung transplant recipients did not appear to be
warranted.39 Additionally, single-agent itraconazole treatment in
heart or lung transplant recipients did not affect the incidence of
fungal infection as compared with a control group.40 To the best
of our knowledge, no deﬁnitive guidelines on the prophylactic
use of azole agents in IPA have been established, and few studies
comparing aerosolized AMB and azole agents for the prevention of
IPA have been performed. One study assessed the efﬁcacy of an
inhaled aqueous solution of voriconazole as prophylaxis against
IPA in a murine model.41 Rodents with IPA that underwent
treatment with inhaled voriconazole demonstrated signiﬁcantly
higher survival than those treated with AMB. However, AMB-d
was administered intraperitoneally. Therefore it remains un-
known whether inhaled voriconazole is superior to aerosolized
AMB. Clinical trials comparing azoles and inhaled AMB are
essential to shed light on the question of which agent and
administration method is optimal for IPA prophylaxis. Mean-
while, cost should be taken into consideration when comparing
different antifungal agents.
Some limitations of this meta-analysis should be noted. First,
because the analysis was limited to the published scientiﬁc
literature, the potential impact of publication bias cannot be
ignored. Publication bias is a known threat to the validity of all
forms of meta-analysis. Journals tend to accept positive results,
while negative results are often rejected or not even submitted
by authors. Second, none of the animal studies in the present
meta-analysis explicitly described the blinding or allocation
concealment methods used. Future studies should clearly
explain the details of their blinding and allocation concealment
methods. Third, all placebo groups in the present studies were
used more than once to compare the effects of the different
interventions. Both the placebo and experimental subgroups in
some eligible studies exhibited a 100% mortality rate. However,
this high mortality rate was not included in the overall estimate
of this meta-analysis, making the combined OR appear to be
much stronger. Fourth, the number of eligible clinical trials
was small. Thus, the relatively small number of participants
might not allow for a reliable conclusion. Fifth, of the two
clinical studies, one did not mention the performance of an
intention-to-treat analysis and was conducted in an unblinded
fashion,22 which may have resulted in high performance,
measurement, and selection biases. Finally, a cost-effectiveness
analysis was not performed; this may have given rise to a
potential preference for the use of aerosolized AMB as
prophylaxis for fungal infections in an era when many other
antifungal drugs are available.
In conclusion, aerosolized AMB effectively reduces the
incidence of IPA in high-risk patients and has proved to be
useful clinically when used as prophylaxis. However, its effects
should be conﬁrmed in large sample-size, multicenter, random-
ized controlled trials. Analysis of cost-effectiveness and adverse
effects between various aerosolized AMB formulations and
newer antifungal agents should be included in future clinical
trials.
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